Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
EV/EBITDA Over TimeExpanding
Percentile Rank100
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-2.08
↑ 87% vs avg
Percentile
P100
Near historical high
Streak
2 yr
Consecutive growthExpanding
Average
-16.20
Historical baseline
PeriodValueYoY Change
2025-2.08+35.0%
2024-3.21+42.3%
2023-5.55-48.0%
2022-3.75+75.1%
2021-15.09+55.0%
2020-33.51+33.3%
2019-50.24-